MARKET

GRFS

GRFS

Grifols S A
NASDAQ
6.86
+0.42
+6.52%
Pre Market: 6.56 -0.3 -4.37% 08:26 10/05 EDT
OPEN
6.37
PREV CLOSE
6.44
HIGH
6.87
LOW
6.37
VOLUME
5.24K
TURNOVER
--
52 WEEK HIGH
15.36
52 WEEK LOW
5.82
MARKET CAP
4.65B
P/E (TTM)
69.64
1D
5D
1M
3M
1Y
5Y
Grifols appoints executive chairman as seeks to speed recovery
Grifols appoints executive chairman as seeks to speed recovery
Reuters · 1d ago
Victor Grifols Roura Decides To Retire As Chair-Person; Grifols Appoints Private Equity Veteran Steven F. Mayer As Executive Chair-Person
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous
Benzinga · 1d ago
GFRS, FWBI and SSNT are among pre market gainers
Ainos (AIMD) +46% <a href="https://seekingalpha.com/pr/18959068-ainos-announces-posi...
Seekingalpha · 5d ago
BRIEF-GigaGen Wins Contract To Discover Synthetic Human Antibody Treatments For Toxins, Pathogens
BRIEF-GigaGen Wins Contract To Discover Synthetic Human Antibody Treatments For Toxins, Pathogens
Reuters · 09/15 14:46
GigaGen Awarded Contract by U.S. Department Of Defense To Discover Synthetic Human Antibody Treatments For High-Priority Toxins And Pathogens; No Terms Disclosed
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint
Benzinga · 09/15 14:32
Grifols Unit Wins Department of Defense Contract to Discover Antibody Treatments for Toxins, Pathogens
Grifols Unit Wins Department of Defense Contract to Discover Antibody Treatments for Toxins, Pathogens
MT Newswires · 09/15 11:52
Grifols inks 15-year deal with Canada for plasma-derived therapies
Spanish biotech Grifols, S.A. (NASDAQ:GRFS) (<a href="https://seeki...
Seekingalpha · 09/07 20:37
Grifols in 15-year deal with Canada for plasma-based medicines
Grifols in 15-year deal with Canada for plasma-based medicines
Reuters · 09/07 16:37
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.